Immunovant, Inc. (IMVT): Total Liabilities
$104.42M
As of 2026-03-31
$117.10M
As of 2026-06-30
+34.1%
3-year compound annual growth
+37.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $104.42M | +51.8% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $68.78M | +41.5% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $48.61M | +12.1% | 2025-05-29, Balance as of period end |
| 2023-03-31 | $43.34M | -5.2% | 2024-05-29, Balance as of period end |
| 2022-03-31 | $45.74M | +117.7% | 2023-05-22, Balance as of period end |
| 2021-03-31 | $21.01M | +37.2% | 2022-06-08, Balance as of period end |
| 2020-03-31 | $15.32M | +136.1% | 2021-06-01, Balance as of period end |
| 2019-03-31 | $6.49M | n/a | 2020-06-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | $104.42M | +51.8% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $237.55M | -4.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $611.11M | -7.6% |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $131.09M | -9.3% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.30B | -40.3% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗